-
-
Percutaneous intervention for peripheral arterial disease (PAD) results in improvement in claudication symptoms but is complicated by a high rate of restenosis.
-
The ACC/AHA guidelines recommend perioperative beta blockers for those already on them, patients undergoing vascular surgery, or those having intermediate- to high-risk surgery with established coronary heart disease, or at high risk of having it.
-
Diabetics are known to have higher rates of restenosis after revascularization than non-diabetic subjects.
-
Optimal management of transmural myocardial infarction (MI) depends on rapid reperfusion of the occluded infarct artery.
-
The resynchronization reverses remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial tested the hypothesis that cardiac resynchronization therapy (CRT) would benefits patients with New York Heart Association (NYHA) functional class I and II heart failure and a prolonged QRS duration.
-
The catheter ablation versus antiarrhythmic Drugs for Atrial Fibrillation (A4) study compared radio-frequency catheter ablation to antiarrhythmic therapy in selected patients with paroxysmal atrial fibrillation (PAF).
-
-
Drug combinations for hypertension; tenecteplase for out-of-hospital cardiac arrest; CAM most commonly used for back, neck, and arthritis pain; FDA Actions.
-
Dual antiplatelet therapy (DAPT) following coronary stenting is essential for the prevention of stent thrombosis, which can occur due to a response to the vascular scaffold, as well as to the local inflammation that occurs after angioplasty. DAPT after drug-eluting stent (DES) implantation is currently recommended for at least 12 months in the United States and for 6 months in Europe.
